---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009784"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:53:02.327936+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences reports preliminary $602M cash; outlines 2026 pipeline milestones

## Summary
- Preliminary unaudited cash $602M as of Dec 31, 2025; runway into 3Q 2028.
- WVE-007 Phase 2a multidose for obesity to start 1H 2026; 400mg 3-mo & 240mg 6-mo data due Q1 2026.
- WVE-006 400mg multidose data from RestorAATion-2 expected Q1 2026; CTA for WVE-008 in 2026.
- NDA filing for WVE-N531 (DMD exon 53 skipping) on track for 2026.
- Plan to submit IND for WVE-003 (Huntington's) with prospective strategic partner.

## SEC filing metadata
- accession: 0001193125-26-009784
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312526009784/0001193125-26-009784-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312526009784/d45710d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009784
- JSON: https://secwatch.observer/filing/0001193125-26-009784.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009784.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.